Li Fangfang, Abdel-Maksoud Mostafa A, Ullah Tahir, Ul Haq Moeen, Khan Abdurrehman, Olatunji Aliu Olalekan, Khatab Abbasi Bakar Bin, Saleh Ibrahim A, Rather Mehak Nabi, Al-Hawadi Jehad S, Zomot Naser, Musaed Almutairi Saeedah, Naz Rida
Department of Gastroenterology, Jiaozhou Central Hospital of Qingdao Qingdao 266300, Shandong, China.
Botany and Microbiology Department, College of Science, King Saud University P.O. Box 2455, Riyadh 11451, Saudi Arabia.
Am J Transl Res. 2024 Dec 15;16(12):7898-7910. doi: 10.62347/MRIE2131. eCollection 2024.
To explore the landscape of BRCA1/2 mutations in gastric cancer patients.
Next-generation sequencing (NGS), Sanger sequencing, reverse transcription quantitative polymerase chain reaction (RT-qPCR), Immunohistochemistry, The Cancer Genome Atlas (TCGA), gnomAD, and DAVID.
With 95% of bases boasting a phred score surpassing 30 and a minimum coverage depth of 500X, our NGS approach ensures high-quality data acquisition. Analyzing BRCA1 and BRCA2 sequences revealed 11 and 4 mutations, respectively, with one pathogenic mutation identified in each gene. This emphasizes the prominence of BRCA1 mutations in gastric cancer. Sanger sequencing validation confirmed the presence of pathogenic mutations in select cases, consolidating our findings. Frequency analysis utilizing the gnomAD database elucidated the rarity of these mutations in the Asian population, underscoring their uniqueness. Exploring TCGA data further corroborated this rarity, emphasizing the distinctive nature of these mutations in gastric cancer. RT-qPCR analysis unveiled a significant reduction in BRCA1/2 expression in samples harboring pathogenic mutations, hinting at their potential role in down-regulating gene expression. Immunohistochemistry confirmed diminished protein expression in samples with pathogenic mutations, solidifying our observations. Kaplan-Meier survival analysis demonstrated significantly poorer survival outcomes for patients with pathogenic BRCA1/2 mutations compared to those without, emphasizing their potential role in prognosis. Additionally, KEGG pathway analysis highlighted the involvement of BRCA1/2 in critical cancer-associated pathways, emphasizing their role in tumorigenesis.
Our comprehensive findings underscore the clinical significance of BRCA1/2 mutations in gastric cancer, advocating for further research to elucidate their mechanistic implications and therapeutic opportunities.
探索胃癌患者中BRCA1/2突变情况。
二代测序(NGS)、桑格测序、逆转录定量聚合酶链反应(RT-qPCR)、免疫组织化学、癌症基因组图谱(TCGA)、gnomAD和DAVID。
我们的NGS方法确保了高质量的数据采集,95%的碱基质量分数超过30,最小覆盖深度为500X。对BRCA1和BRCA2序列分析分别发现了11个和4个突变,每个基因中鉴定出1个致病突变。这突出了BRCA1突变在胃癌中的突出地位。桑格测序验证证实在部分病例中存在致病突变,巩固了我们的研究结果。利用gnomAD数据库进行的频率分析阐明了这些突变在亚洲人群中的罕见性,凸显了它们的独特性。进一步探索TCGA数据进一步证实了这种罕见性,强调了这些突变在胃癌中的独特性质。RT-qPCR分析显示,携带致病突变的样本中BRCA1/2表达显著降低,提示它们在下调基因表达方面的潜在作用。免疫组织化学证实在有致病突变的样本中蛋白质表达减少,巩固了我们的观察结果。Kaplan-Meier生存分析表明,与无致病BRCA1/2突变的患者相比,有致病突变的患者生存结果明显更差,强调了它们在预后中的潜在作用。此外,KEGG通路分析突出了BRCA1/2参与关键的癌症相关通路,强调了它们在肿瘤发生中的作用。
我们的综合研究结果强调了BRCA1/2突变在胃癌中的临床意义,倡导进一步研究以阐明其机制影响和治疗机会。